Showing 2,041 - 2,060 results of 2,299 for search 'Patient Number 9', query time: 0.10s Refine Results
  1. 2041
  2. 2042
  3. 2043
  4. 2044
  5. 2045
  6. 2046

    Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma by Tingting Zhang, Tianyuan Ren, Zheng Song, Jing Zhao, Lei Jiao, Zhenzhen Zhang, Jin He, Xianming Liu, Lihua Qiu, Lanfang Li, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Zhengzi Qian, Xianhuo Wang, Huilai Zhang

    Published 2020-01-01
    “…Herein, we identified three genetic mutations in galectin-9, a major ligand of Tim-3, in six patients with DLBCL (6/188, 3.2%) that were not detected in the COSMIC database. …”
    Get full text
    Article
  7. 2047
  8. 2048

    L-glutaminase synthesis by Klebsiella pneumoniae (AS KP 23) isolated from clinical strain, and its efficacy against human hepatocellular and breast cancer cell lines by Lina J. Abdel-Hafez, Eman Y. T. Elariny, Asmaa E. Ibrahim, Mahmoud E. F. Abdel-Haliem

    Published 2025-02-01
    “…Subsequently, L-glutaminase was administered intravenously in patients with acute lymphoblastic leukemia and acute myeloid leukemia. …”
    Get full text
    Article
  9. 2049

    Changes in infant respiratory pathogens pre-, during, and post-COVID-19 non-pharmacological interventions in Beijing by Tongying Han, Yajuan Wang, Di Zhang, Ying Li, Li Zhang, Jin Yan, Chi Li, Shengnan Yang, Litao Guo, Huijuan Yan

    Published 2025-01-01
    “…Prior to the epidemic, these rates were 11.9% (431/3611), 37.1% (160/431), and 5.0% (8/160), respectively. …”
    Get full text
    Article
  10. 2050
  11. 2051

    Respiratory pathogen spectrum and epidemiological trends in Hainan Province: a retrospective analysis from 2017 to 2023 by Lvying Wu, Jianan Zhang, Zhiming Wu, Hua Pei, You Zhang

    Published 2025-02-01
    “…Results During 2017–2023, the number of RTI patients and pathogen detection rate was gradually decrease from 33.30% (3,886/11,670; pre-COVID-19), to 30.81% (2,034/6,602; NPI) and 22.43% (620/2,764; COVID-19). …”
    Get full text
    Article
  12. 2052

    Safety and efficacy of total colectomy with D3 lymph node dissection at colorectal cancer, developed at inflammatory bowel diseases (case control study) by P. V. Tsarkov, I. A. Tulina, S. K. Efetov, Yu. E. Kitsenko, D. N. Fedorov

    Published 2018-08-01
    “…Overall 6 IBD-CRC and 18 spCRC patients were matched. IBD-CRC patients had longer operation time (313±37 vs 240±16 min, p=0.05), while there was no significant difference in mean volume of blood loss and postoperative stay duration (383±145 and 186±29 ml, p=0.24; 15.7±3.2 and 14.1±0.9 days, p=0.5 respectively). …”
    Get full text
    Article
  13. 2053
  14. 2054
  15. 2055
  16. 2056
  17. 2057
  18. 2058
  19. 2059
  20. 2060

    Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis by Huan Zhang, Jing Huang, Huanji Xu, Nanhao Yin, Nanhao Yin, Liyan Zhou, Liyan Zhou, Jianxin Xue, Jianxin Xue, Jianxin Xue, Min Ren

    Published 2025-01-01
    “…Non-metastatic pMMR/MSS RC patients receiving SCRT, PD-1 inhibitors, or concurrent immuno-radiotherapy in the neoadjuvant setting exhibited enhanced outcomes. …”
    Get full text
    Article